血小板计数在原发性血小板增多症患者行α-干扰素联合羟基脲治疗中的临床研究  

Platelet Count in Patients with Primary Thrombocytosis α-Clinical Study of Interferon Combined with Hydroxyurea in Treatment

作　　者：翁羽蕙 庄世民[1] 刘亮[1] WENG Yuhui;ZHUANG Shimin;LIU Liang(Department of Hematology,Fuqing City Hospital,Fujian Medical University,Fuqing 350300,China)

机构地区：[1]福建医科大学附属福清市医院血液科,福建福州350300

出　　处：《中国医药指南》2023年第14期64-66,共3页Guide of China Medicine

摘　　要：目的 研究血小板计数在原发性血小板增多症患者行α-干扰素联合羟基脲治疗中的血栓形成预测价值。方法 选取2021年10月至2022年9月收治的行α-干扰素联合羟基脲治疗的46例原发性血小板增多症患者进行分析,将患者根据原发性血小板增多症血栓国际预后积分(IPSET-thrombosis)系统的评估结果进行分组,即低危、中危、高危3组。比较各组血小板计数的差异,并以ROC曲线分析血小板计数预测原发性血小板增多症患者血栓高风险的价值。结果 3组患者在治疗前与治疗2周时的血小板计数差异无统计学意义(P> 0.05);在治疗4周时高危组的血小板计数稍高于低危组与中危组(P <0.05),此时低危组与中危组之间的血小板计数差异无统计学意义(P> 0.05);在治疗6、8周时,高危组的血小板计数高于低危组与中危组(P <0.05),此时中危组的血小板计数水平高于低危组(P <0.05)。治疗4、6、8周时分别检测到的血小板计数对原发性血小板增多症患者血栓形成高风险的最佳预测界值分别为645.77×10^(9)/L、638.68×10^(9)/L、622.42×10^(9)/L,约登指数分别为0.607、0.724、0.729。结论 在原发性血小板增多症患者行α-干扰素联合羟基脲治疗过程中,检测血小板计数对其血栓形成高风险具有一定预测价值,血小板计数在治疗6周时> 638.68×10^(9)/L或者8周时> 622.42×10^(9)/L,应警惕患者血栓发生。Objective To study the platelet count in patients with primary thrombocytosis(ET)α-the predictive value of interferon combined with hydroxyurea in the treatment of thrombosis.Methods The patients admitted from October 2021 to September 2022 were selectedα-46 patients with ET treated with interferon and hydroxyurea were analyzed,and the patients were divided into three groups according to the evaluation results of the International Prognosis Score of ET Thrombosis(IPSET-thrombosis)system,namely,low risk,medium risk and high risk groups.Compare the difference of platelet count in each group,and analyze the value of platelet count to predict the high risk of thrombosis in ET patients with ROC curve.Results There was no significant difference in platelet count between the three groups before and after treatment for 2 weeks(P>0.05).At the 4th week of treatment,the platelet count of high-risk group was slightly higher than that of low-risk group and medium-risk group(P<0.05).At the 6th and 8th week of treatment,the platelet count of high-risk group was higher than that of low-risk group and medium-risk group(P<0.05).The best predictive threshold of platelet counts detected at 4,6 and 8 weeks of treatment for the high risk of thrombosis in ET patients was 645.77×10^(9)/L,638.68×10^(9)/L,622.42×10^(9)/L,Yoden index is 0.607,0.724 and 0.729 respectively.Conclusion In patients with ETα-During the treatment of interferon combined with hydroxyurea,the detection of platelet count has certain predictive value for the high risk of thrombosis,and platelet counts>638.68×10^(9)/L at 6 weeks or>622.42×10^(9)/L at 8 weeks,and patients should be alerted to thrombosis risk.

关 键 词：原发性血小板增多症 血小板计数 Α-干扰素 羟基脲 血栓 

分 类 号：R558[医药卫生—血液循环系统疾病]